Summary
In a significant market movement during December 2022, Storm Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £24,260,869. Leading the round was UTokyo Innovation Platform, Fast Track Initiative, IP Group PLC, M Ventures, Seroba Life Sciences, Taiho Ventures LLC, Pfizer Ventures, Cambridge Innovation Capital.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
UTokyo Innovation Platform
Lead Investor / Acquirer
Fast Track Initiative
Lead Investor / Acquirer
IP Group PLC
Lead Investor / Acquirer
M Ventures
Lead Investor / Acquirer
Seroba Life Sciences
Lead Investor / Acquirer
Taiho Ventures LLC
Lead Investor / Acquirer
Pfizer Ventures
Lead Investor / Acquirer
Cambridge Innovation Capital
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series B prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in